Immunovant, Inc. filings document the formal disclosures of a clinical-stage immunology company developing anti-FcRn product candidates for autoimmune diseases. Recent Form 8-K reports cover quarterly financial results, operating updates, research and development activity, clinical program communications for Graves’ disease and related indications, financing disclosure and other material events.
Proxy and governance filings describe annual meeting matters, director elections, auditor ratification, executive compensation, equity awards and stockholder voting results. Officer-transition and compensation-related 8-Ks add detail on employment agreements, severance arrangements, consulting services and incentive awards, while the company’s disclosures frame capital structure and governance around its single development-focused operating segment.
A holder of IMVT common stock has filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 5,800 common shares through Morgan Stanley Smith Barney LLC, with an approximate sale date of February 10, 2026 on the NASDAQ.
The shares to be sold were acquired as restricted stock from the issuer in January 2026 in two grants of 3,770 and 2,030 shares, both fully paid on their acquisition dates. The filing also lists recent sales of common shares by Michael Geffner over the prior three months, including multiple transactions in November 2025 and January 2026.
Immunovant, Inc. reported another quarter of heavy investment in its autoimmune pipeline, led by FcRn inhibitor IMVT-1402, with no product revenue yet. For the three months ended December 31, 2025, net loss was $110.6 million, similar to the prior year.
Quarterly research and development expenses were $98.9 million, reflecting multiple potentially registrational trials across Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, CIDP and Sjögren’s disease, plus a proof‑of‑concept study in cutaneous lupus. General and administrative expenses fell to $15.4 million as corporate spending moderated.
The company strengthened its balance sheet with a December 2025 underwritten equity offering of 26.2 million shares at $21.00, generating net proceeds of $543.6 million. Cash and cash equivalents rose to $994.5 million as of December 31, 2025, which management believes can fund announced indications through a potential commercial launch of IMVT-1402 in Graves’ disease.
Immunovant, Inc. reported a fiscal third-quarter 2025 net loss of $110.6 million, or $0.61 per share, driven mainly by research and development spending as it advances its autoimmune pipeline.
For the quarter ended December 31, 2025, R&D expenses were $98.9 million and general and administrative expenses were $15.4 million, with non-GAAP R&D and G&A at $91.1 million and $10.6 million, respectively. Nine-month net loss totaled $357.8 million, or $2.04 per share, with non-GAAP net loss of $312.9 million.
Cash and cash equivalents reached $994.5 million as of December 31, 2025, supported by an underwritten financing that generated approximately $550 million in gross proceeds, which the company believes extends its cash runway to the potential launch of IMVT-1402 in Graves’ disease. Key programs include a fully enrolled potentially registrational trial of IMVT-1402 in difficult-to-treat rheumatoid arthritis, with topline data expected in the second half of 2026, additional potentially registrational IMVT-1402 trials across several autoimmune indications, and Phase 3 batoclimab data in thyroid eye disease expected in the first half of 2026.
Immunovant Chief Technology Officer Jay S. Stout reported selling 1,977 shares of common stock at $26.03 per share. After this sale, he beneficially owns 197,634 shares directly.
The filing explains that this sale was not a discretionary trade. It was a mandated “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units. Of an earlier grant of 100,000 RSUs made on April 17, 2023, 6,250 RSUs vested on January 17, 2026, triggering the tax-related sale.
Immunovant, Inc. reported insider share sales by its Chief Technology Officer, Jay Stout, tied to RSU tax withholding. On January 7, 2026, he sold 1,148 shares of common stock at a weighted average price of $26.51 per share and 55 shares at a weighted average price of $26.92 per share. These sales were executed to cover tax withholding obligations from the vesting and settlement of restricted stock units and were mandated by the company’s “sell to cover” election, rather than being discretionary trades. Following the reported transactions, he directly held 199,611 shares of Immunovant common stock.
Immunovant, Inc. is offering 26,200,000 shares of common stock at $21.00 per share, for gross proceeds of $550.2 million. Roivant Sciences, its controlling shareholder, has agreed to buy 16,666,666 of these shares at the same price, and the underwriter will not receive fees on Roivant’s portion.
The company expects to receive approximately $543.7 million in net proceeds, which it plans to use, together with existing cash, primarily to advance clinical trials of its lead anti-FcRn antibody IMVT-1402, with any remainder for working capital and other general corporate purposes. Management currently expects this capital, plus cash on hand, to fund operating expenses and capital expenditures through the potential commercial launch of IMVT-1402 for Graves’ disease.
Immunovant is a clinical-stage immunology company developing IMVT-1402 and batoclimab for multiple autoimmune, autoantibody-driven diseases, including difficult-to-treat rheumatoid arthritis, Graves’ disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease. The offering will increase net tangible book value per share from $2.98 to an estimated $5.30, but investors paying $21.00 per share will face immediate dilution of $15.70 per share.
Immunovant, Inc. (IMVT) reported an insider transaction by its Chief Operating Officer, Melanie Gloria. On November 20, 2025, she sold 10,251 shares of common stock at a weighted average price of $23.54 per share and an additional 2,375 shares at a weighted average price of $23.97 per share.
These sales were made to cover tax withholding obligations related to the vesting and settlement of previously granted restricted stock units, following the company’s required “sell to cover” procedure. After these transactions, she beneficially owned 173,511 shares of Immunovant common stock directly.
Immunovant, Inc. reported that Michael Geffner, M.D., M.B.A., ceased serving as its Chief Medical Officer effective November 21, 2025, as part of a restructuring of the company’s R&D leadership under Chief Executive Officer Eric Venker, M.D., PharmD. The company and Dr. Geffner entered into a Separation Agreement and General Release that provides severance benefits consistent with his existing employment agreement and includes a standard release of claims in favor of the company.
To support continuity, Dr. Geffner will provide consulting services through April 30, 2026. During this consulting period, his outstanding equity awards will continue to vest under their current terms, and any unvested awards scheduled to vest during the consulting period will fully vest if a change in control occurs in that timeframe. Vested stock options may be exercised until the earlier of nine months after his consulting ends or their original expiration dates.
Immunovant (IMVT) filed its quarterly report for the period ended September 30, 2025. The company reported a net loss of $126.5 million for the quarter and $247.1 million for the six-month period, reflecting increased investment in clinical programs. Loss per share was $0.73 for the quarter and $1.43 year-to-date.
Research and development expenses rose to $114.2 million in the quarter (from $97.3 million), driven by potentially registrational trials across endocrine (Graves’ disease), neurology (myasthenia gravis, CIDP), rheumatology (difficult-to-treat RA, Sjögren’s), and a proof-of-concept in dermatology (cutaneous lupus). General and administrative expenses declined to $17.5 million from $18.5 million.
Cash and cash equivalents were $521.9 million, with operating cash outflows of $219.9 million for the six months. Management states this balance is expected to fund announced indications through the Graves’ disease readout in 2027. Shares outstanding were 174,532,710 as of September 30, 2025. The company has an unused at-the-market program of up to $150.0 million and a remaining $39.1 million minimum obligation for batoclimab manufacturing.
Immunovant, Inc. furnished an 8-K announcing a press release with financial results for its fiscal second quarter and six months ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information under Item 2.02, including Exhibit 99.1, is furnished, not deemed “filed” under the Exchange Act, and will not be incorporated by reference in other SEC filings. The report was signed by Chief Financial Officer Tiago Girao.